#METABOLOMICS WORKBENCH DATATRACK_ID:3929 STUDY_ID:ST002613 ANALYSIS_ID:AN004285 VERSION 1 CREATED_ON 02-08-2024 #PROJECT PR:PROJECT_TITLE MoTrPAC PR:PROJECT_SUMMARY MoTrPAC is a national research consortium designed to discover and perform PR:PROJECT_SUMMARY preliminary characterization of the range of molecular transducers (the PR:PROJECT_SUMMARY "molecular map") that underlie the effects of physical activity in humans. The PR:PROJECT_SUMMARY program's goal is to study the molecular changes that occur during and after PR:PROJECT_SUMMARY exercise and ultimately to advance the understanding of how physical activity PR:PROJECT_SUMMARY improves and preserves health. Preclinical and clinical studies will examine the PR:PROJECT_SUMMARY systemic effects of endurance and resistance exercise across a range of ages and PR:PROJECT_SUMMARY fitness levels by molecular probing of multiple tissues before and after acute PR:PROJECT_SUMMARY and chronic exercise. This program is the largest targeted NIH investment of PR:PROJECT_SUMMARY funds into the mechanisms of how physical activity improves health and prevents PR:PROJECT_SUMMARY disease. The MoTrPAC program is supported by the NIH Common Fund and is managed PR:PROJECT_SUMMARY by a trans-agency working group representing multiple NIH institutes and PR:PROJECT_SUMMARY centers, led by the NIH Office of Strategic Coordination, National Institute of PR:PROJECT_SUMMARY Arthritis and Musculoskeletal and Skin Diseases, National Institute of Diabetes PR:PROJECT_SUMMARY and Digestive and Kidney Diseases, National Institute on Aging, and National PR:PROJECT_SUMMARY Institute of Biomedical Imaging and Bioengineering. MoTrPAC Steering Committee: PR:PROJECT_SUMMARY Wendy Kohrt, Chair, Russ Tracy, Co-Chair; NIH Program Manager, Concepcion PR:PROJECT_SUMMARY Nierras. Euan Ashley and Matthew Wheeler are the PIs for the Motrpac PR:PROJECT_SUMMARY Bioinformatics / Data Coordination Center. PR:INSTITUTE MoTrPAC PR:LAST_NAME Ashley PR:FIRST_NAME Euan PR:ADDRESS Falk Building CV267, 870 Quarry Road, Stanford, California 94305 PR:EMAIL motrpac-data-deposition@lists.stanford.edu PR:PHONE (650) 725-1846 PR:DOI http://dx.doi.org/10.21228/M8V97D #STUDY ST:STUDY_TITLE MoTrPAC: Endurance exercise training study in young adult rats, Tissue:Liver - ST:STUDY_TITLE Targeted Ethanolamides ST:STUDY_SUMMARY The goal of the endurance exercise training study in young adult rats (internal ST:STUDY_SUMMARY code: PASS1B-06) was to perform exercise training studies in adult (6 month) ST:STUDY_SUMMARY F344 rats, and from these rats collect as many tissues as feasible in order to ST:STUDY_SUMMARY provide high quality samples for detailed analysis by chemical analysis sites. ST:STUDY_SUMMARY Tissues were collected from 10-12 rats sedentary control rats concurrent with ST:STUDY_SUMMARY the collection of the 8-week training groups. The 8-week training group and ST:STUDY_SUMMARY controls were from the same cohort and same age at euthanasia (either 8). For ST:STUDY_SUMMARY the older age group, an additional set of controls (n=5-6) were collected with ST:STUDY_SUMMARY the 1-2 week training group. Rats were either sedentary or underwent an exercise ST:STUDY_SUMMARY training program. Rats were exercised on the rodent treadmill 5 days per week ST:STUDY_SUMMARY using a progressive training protocol designed to exercise the rats at ST:STUDY_SUMMARY approximately 70% of VO2max as outlined in the Table on the next page. Training ST:STUDY_SUMMARY was performed no earlier than 10:00 am and no later than 5:00 pm over 5 ST:STUDY_SUMMARY consecutive days per week. Training was initiated with the treadmill set at 70% ST:STUDY_SUMMARY of VO2 max (see tables) and 5 degrees grade for 20 minutes. The duration of ST:STUDY_SUMMARY exercise was increased by one minute each day until day 31 of training (start of ST:STUDY_SUMMARY week 7), when a duration of 50 min was reached. Speed and grade of each training ST:STUDY_SUMMARY session increased in larger increments due to treadmill parameters. The highest ST:STUDY_SUMMARY intensity and duration of training began on day 31. This intensity was ST:STUDY_SUMMARY maintained for the final 10 days of the protocol to ensure steady state had been ST:STUDY_SUMMARY achieved. If any rats were unable to perform at least 4 days of training per ST:STUDY_SUMMARY week they were removed from the study and euthanized. It is important to note ST:STUDY_SUMMARY that the starting treadmill speed varied depending on the sex and age of the ST:STUDY_SUMMARY rat. The initial and maximum speeds were based on VO2max measurements obtained ST:STUDY_SUMMARY during the pre-training testing of the compliant rats. Rats assigned to the ST:STUDY_SUMMARY control group followed a schedule similar to the training group. They were ST:STUDY_SUMMARY placed in one lane on the treadmill for 15 minutes/day, 5 days per week. The ST:STUDY_SUMMARY treadmill was set at 0 m/min at an incline that corresponded to the incline ST:STUDY_SUMMARY being used by the training group. ST:INSTITUTE Emory University ST:DEPARTMENT Biochemistry ST:LABORATORY Integrated Lipidomics and Metabolomics Core ST:LAST_NAME Ortlund ST:FIRST_NAME Eric ST:ADDRESS 1510 Clifton Rd. NE, Room G235, Atlanta, GA 30322 ST:EMAIL eortlun@emory.edu ST:PHONE (404) 727-5014 ST:SUBMIT_DATE 2023-04-28 #SUBJECT SU:SUBJECT_TYPE Mammal SU:SUBJECT_SPECIES Rattus norvegicus SU:TAXONOMY_ID 10116 #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data SUBJECT_SAMPLE_FACTORS 1628FB23-6F66-47D4-8D82-63C87726F0FD 90245016810 Group:Control | Timepoint:8 weeks of training or control time | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 69FD4884-786D-4F2A-97B1-6174FBD25D60 90248016810 Group:Control | Timepoint:8 weeks of training or control time | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 07AF7369-F082-4CA7-99D5-D973F4A162C9 90252016810 Group:Control | Timepoint:8 weeks of training or control time | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS F9BEE1FA-E2DB-4BE4-A79C-99D585D6FD17 90265016810 Group:Control | Timepoint:8 weeks of training or control time | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS A77AC89A-1D9E-4516-9DA4-2BE99C8126EF 90266016810 Group:Control | Timepoint:8 weeks of training or control time | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS BC49E4EF-E2FE-4269-BAF0-461F768BD95D 90217016810 Group:Control | Timepoint:8 weeks of training or control time | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 0559B193-BED3-4170-B045-10A2B6441CB6 90229016810 Group:Control | Timepoint:8 weeks of training or control time | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 90CFE5A4-76FE-4458-A2B1-A66F0B60118E 90232016810 Group:Control | Timepoint:8 weeks of training or control time | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS F0D83B29-8EFA-4CDE-B1AA-2358AC220ECF 90237016810 Group:Control | Timepoint:8 weeks of training or control time | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS FCE9ABE6-B60B-4934-BAE5-56AF8B11ECEC 90239016810 Group:Control | Timepoint:8 weeks of training or control time | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_blank_4 Group:QC-Blank | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_blank_66 Group:QC-Blank | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_blank_68 Group:QC-Blank | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_blank_69 Group:QC-Blank | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_blank_78 Group:QC-Blank | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_blank_79 Group:QC-Blank | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_Standard_70 Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_Standard_71 Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_Standard_72 Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_Standard_73 Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_Standard_74 Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_Standard_75 Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_Standard_76 Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_Standard_77 Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_18 Group:QC-Pooled | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_29 Group:QC-Pooled | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_40 Group:QC-Pooled | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_51 Group:QC-Pooled | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_62 Group:QC-Pooled | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_67 Group:QC-Pooled | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_7 Group:QC-Pooled | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_prerun_1 Group:QC-PreRun | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_prerun_2 Group:QC-PreRun | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_prerun_3 Group:QC-PreRun | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - G_QC_1_5 Group:QC-Reference | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - G_QC_1_63 Group:QC-Reference | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - G_QC_2_6 Group:QC-Reference | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - G_QC_2_64 Group:QC-Reference | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS - QC_SRM Group:QC-Reference | Timepoint:0 hour | Sex:- raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS B73AB139-7210-4498-9CCF-E1DBE6EBA71C 90559016810 Group:Training | Timepoint:1 week of training or control time | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS EA5C8932-9325-4DA5-96BB-50CD49CEDD10 90560016810 Group:Training | Timepoint:1 week of training or control time | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 0645F621-878C-4C9B-84A6-58862BAA17D9 90564016810 Group:Training | Timepoint:1 week of training or control time | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 68083256-8DAA-4185-B446-0CAF600474B5 90567016810 Group:Training | Timepoint:1 week of training or control time | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 6A013AA1-4D1E-4B75-B691-6BA22D928E51 90571016810 Group:Training | Timepoint:1 week of training or control time | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 6D680EA2-C62B-4A35-8B6E-2ED6A79CB017 90421016810 Group:Training | Timepoint:1 week of training or control time | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 53F914B0-FD4F-4340-84A6-48341EAB3798 90422016810 Group:Training | Timepoint:1 week of training or control time | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS D350D633-8D95-4783-99F2-BB8294D2EC32 90423016810 Group:Training | Timepoint:1 week of training or control time | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 0DBFEB04-1B58-43CF-BAFD-9AA9915B67F6 90426016810 Group:Training | Timepoint:1 week of training or control time | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 10E282EB-1DBA-406E-BD5D-81027083A01D 90430016810 Group:Training | Timepoint:1 week of training or control time | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS B137E81D-A9DE-4E3A-8E2B-AD6C22920B7E 90576016810 Group:Training | Timepoint:2 weeks of training | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS DC8B35E8-4AA8-4829-8569-F223D069620C 90578016810 Group:Training | Timepoint:2 weeks of training | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 8904857C-2073-4BBA-AC7C-1EC239E5BFF7 90581016810 Group:Training | Timepoint:2 weeks of training | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 1F9BD644-303F-43E7-94BE-FF6654306F5E 90585016810 Group:Training | Timepoint:2 weeks of training | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 0409BED3-F9FE-4C06-9920-74F5E5CA04A3 90587016810 Group:Training | Timepoint:2 weeks of training | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 4E974304-21EB-42E8-A729-A7FB6B406E64 90439016810 Group:Training | Timepoint:2 weeks of training | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 6527EC12-E7EB-4F17-BF0A-0AC7CD1819A0 90441016810 Group:Training | Timepoint:2 weeks of training | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS AEB1611A-F29E-43F8-B9F3-A2BC4F9EB504 90444016810 Group:Training | Timepoint:2 weeks of training | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS FDA87A8D-3634-4C42-9A1A-0EA03B58BB01 90449016810 Group:Training | Timepoint:2 weeks of training | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS CDCFA3F1-07ED-4737-A36D-15EFEC325AA5 90450016810 Group:Training | Timepoint:2 weeks of training | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 2E37478F-525F-4E5E-A882-EE75FD0CFB29 90406016810 Group:Training | Timepoint:4 weeks of training | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS A9CE3E3D-31A0-4443-8A7F-8FD831D79248 90410016810 Group:Training | Timepoint:4 weeks of training | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 3D5BC47C-BB3D-45A2-8DB8-D7ADCD51997C 90412016810 Group:Training | Timepoint:4 weeks of training | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 89D6F615-D17C-4EB9-88EB-A602940FF179 90416016810 Group:Training | Timepoint:4 weeks of training | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS FE012DC0-AF32-4C70-A4D4-F042B8BC4EC6 90420016810 Group:Training | Timepoint:4 weeks of training | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 22D700B9-EDD0-4BC8-8155-EB9C39417F81 90280016810 Group:Training | Timepoint:4 weeks of training | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 1CA4210C-3CE6-4A5A-996B-673EBDEB3B81 90281016810 Group:Training | Timepoint:4 weeks of training | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 9F3E1040-D409-421E-B635-2572DC20ED89 90283016810 Group:Training | Timepoint:4 weeks of training | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 569A9229-04E8-414A-A195-FE9E8F1B66AB 90289016810 Group:Training | Timepoint:4 weeks of training | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS E4271AF1-899A-4A65-9D8D-BF18CEE3F1CF 90292016810 Group:Training | Timepoint:4 weeks of training | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 0D5071F5-D166-4CF1-BE8B-EB4DF6E04C0E 90251016810 Group:Training | Timepoint:8 weeks of training or control time | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 2479BEE5-2A38-4D09-B15B-B1715F561A9F 90254016810 Group:Training | Timepoint:8 weeks of training or control time | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 0A4A7935-3AF4-463F-84E3-DCF07671509D 90258016810 Group:Training | Timepoint:8 weeks of training or control time | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 04C84D7E-FC8C-422F-AE4B-CAFADB63407B 90259016810 Group:Training | Timepoint:8 weeks of training or control time | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 2B969165-1A52-43AA-8FD9-39AFA62F094F 90267016810 Group:Training | Timepoint:8 weeks of training or control time | Sex:Female raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 0BD282C7-7832-4581-9089-08A32D557034 90218016810 Group:Training | Timepoint:8 weeks of training or control time | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 955498F4-70A0-4D50-A2BA-619A8FED8FEF 90222016810 Group:Training | Timepoint:8 weeks of training or control time | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS CFE06932-9314-4BCC-B2D9-73883D5FCDFB 90223016810 Group:Training | Timepoint:8 weeks of training or control time | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS 3719CB62-B551-49BE-94A0-E51DFE13D30D 90225016810 Group:Training | Timepoint:8 weeks of training or control time | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff SUBJECT_SAMPLE_FACTORS F65955CE-E49F-48C7-B861-02A2FDF6F9B8 90227016810 Group:Training | Timepoint:8 weeks of training or control time | Sex:Male raw_file=MoTrPAc_liver_pass1b_pos_V1-20200828.wiff #COLLECTION CO:COLLECTION_SUMMARY - CO:SAMPLE_TYPE Liver #TREATMENT TR:TREATMENT_SUMMARY - #SAMPLEPREP SP:SAMPLEPREP_SUMMARY purification of oxylipids with SPE column SP:SAMPLEPREP_PROTOCOL_FILENAME pass1b_experimental_design_metabolomics.pdf #CHROMATOGRAPHY CH:CHROMATOGRAPHY_SUMMARY Lipids were separated by liquid chromatography with 20 minutes gradient CH:METHODS_FILENAME pass1b_oxylipneg_etamidpos_methods.pdf CH:INSTRUMENT_NAME ExionLC AC CH:COLUMN_NAME ThermoScientific Accucore C18 (100 x 4.6mm, 2.6um) CH:COLUMN_TEMPERATURE 50C CH:FLOW_GRADIENT t=0 min: 90%/10% (%A/%B) @ 0.5 ml/min | t=0.5 min: 90%/10% (%A/%B) @ 0.5 ml/min CH:FLOW_GRADIENT | t=1 min: 50%/50% (%A/%B) @ 0.5 ml/min | t=2 min: 50%/50% (%A/%B) @ 0.5 ml/min CH:FLOW_GRADIENT | t=2.1 min: 25%/75% (%A/%B) @ 0.5 ml/min | t=5 min: 25%/75% (%A/%B) @ 0.5 CH:FLOW_GRADIENT ml/min | t=7 min: 15%/85% (%A/%B) @ 0.5 ml/min | t=12 min: 15%/85% (%A/%B) @ 0.5 CH:FLOW_GRADIENT ml/min | t=12.1 min: 90%/10% (%A/%B) @ 0.5 ml/min | t=18 min: 90%/10% (%A/%B) @ CH:FLOW_GRADIENT 0.5 ml/min CH:FLOW_RATE 0.5 ml/min CH:SOLVENT_A 100% water; 10 mM ammonium acetate CH:SOLVENT_B 100% acetonitrile; 10 mM ammonium acetate CH:CHROMATOGRAPHY_TYPE Reversed phase #ANALYSIS AN:ANALYSIS_TYPE MS #MS MS:INSTRUMENT_NAME ABI Sciex 5500 Qtrap MS:INSTRUMENT_TYPE Triple quadrupole MS:MS_TYPE ESI MS:MS_COMMENTS Multiple reaction monitoring mode (MRM) MS:ION_MODE POSITIVE #MS_METABOLITE_DATA MS_METABOLITE_DATA:UNITS ng/uL MS_METABOLITE_DATA_START Samples 90245016810 90248016810 90252016810 90265016810 90266016810 90217016810 90229016810 90232016810 90237016810 90239016810 QC_blank_4 QC_blank_66 QC_blank_68 QC_blank_69 QC_blank_78 QC_blank_79 QC_Standard_70 QC_Standard_71 QC_Standard_72 QC_Standard_73 QC_Standard_74 QC_Standard_75 QC_Standard_76 QC_Standard_77 QC_18 QC_29 QC_40 QC_51 QC_62 QC_67 QC_7 QC_prerun_1 QC_prerun_2 QC_prerun_3 G_QC_1_5 G_QC_1_63 G_QC_2_6 G_QC_2_64 QC_SRM 90559016810 90560016810 90564016810 90567016810 90571016810 90421016810 90422016810 90423016810 90426016810 90430016810 90576016810 90578016810 90581016810 90585016810 90587016810 90439016810 90441016810 90444016810 90449016810 90450016810 90406016810 90410016810 90412016810 90416016810 90420016810 90280016810 90281016810 90283016810 90289016810 90292016810 90251016810 90254016810 90258016810 90259016810 90267016810 90218016810 90222016810 90223016810 90225016810 90227016810 Factors Group:Control | Timepoint:8 weeks of training or control time | Sex:Female Group:Control | Timepoint:8 weeks of training or control time | Sex:Female Group:Control | Timepoint:8 weeks of training or control time | Sex:Female Group:Control | Timepoint:8 weeks of training or control time | Sex:Female Group:Control | Timepoint:8 weeks of training or control time | Sex:Female Group:Control | Timepoint:8 weeks of training or control time | Sex:Male Group:Control | Timepoint:8 weeks of training or control time | Sex:Male Group:Control | Timepoint:8 weeks of training or control time | Sex:Male Group:Control | Timepoint:8 weeks of training or control time | Sex:Male Group:Control | Timepoint:8 weeks of training or control time | Sex:Male Group:QC-Blank | Timepoint:0 hour | Sex:- Group:QC-Blank | Timepoint:0 hour | Sex:- Group:QC-Blank | Timepoint:0 hour | Sex:- Group:QC-Blank | Timepoint:0 hour | Sex:- Group:QC-Blank | Timepoint:0 hour | Sex:- Group:QC-Blank | Timepoint:0 hour | Sex:- Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- Group:QC-ExternalStandard | Timepoint:0 hour | Sex:- Group:QC-Pooled | Timepoint:0 hour | Sex:- Group:QC-Pooled | Timepoint:0 hour | Sex:- Group:QC-Pooled | Timepoint:0 hour | Sex:- Group:QC-Pooled | Timepoint:0 hour | Sex:- Group:QC-Pooled | Timepoint:0 hour | Sex:- Group:QC-Pooled | Timepoint:0 hour | Sex:- Group:QC-Pooled | Timepoint:0 hour | Sex:- Group:QC-PreRun | Timepoint:0 hour | Sex:- Group:QC-PreRun | Timepoint:0 hour | Sex:- Group:QC-PreRun | Timepoint:0 hour | Sex:- Group:QC-Reference | Timepoint:0 hour | Sex:- Group:QC-Reference | Timepoint:0 hour | Sex:- Group:QC-Reference | Timepoint:0 hour | Sex:- Group:QC-Reference | Timepoint:0 hour | Sex:- Group:QC-Reference | Timepoint:0 hour | Sex:- Group:Training | Timepoint:1 week of training or control time | Sex:Female Group:Training | Timepoint:1 week of training or control time | Sex:Female Group:Training | Timepoint:1 week of training or control time | Sex:Female Group:Training | Timepoint:1 week of training or control time | Sex:Female Group:Training | Timepoint:1 week of training or control time | Sex:Female Group:Training | Timepoint:1 week of training or control time | Sex:Male Group:Training | Timepoint:1 week of training or control time | Sex:Male Group:Training | Timepoint:1 week of training or control time | Sex:Male Group:Training | Timepoint:1 week of training or control time | Sex:Male Group:Training | Timepoint:1 week of training or control time | Sex:Male Group:Training | Timepoint:2 weeks of training | Sex:Female Group:Training | Timepoint:2 weeks of training | Sex:Female Group:Training | Timepoint:2 weeks of training | Sex:Female Group:Training | Timepoint:2 weeks of training | Sex:Female Group:Training | Timepoint:2 weeks of training | Sex:Female Group:Training | Timepoint:2 weeks of training | Sex:Male Group:Training | Timepoint:2 weeks of training | Sex:Male Group:Training | Timepoint:2 weeks of training | Sex:Male Group:Training | Timepoint:2 weeks of training | Sex:Male Group:Training | Timepoint:2 weeks of training | Sex:Male Group:Training | Timepoint:4 weeks of training | Sex:Female Group:Training | Timepoint:4 weeks of training | Sex:Female Group:Training | Timepoint:4 weeks of training | Sex:Female Group:Training | Timepoint:4 weeks of training | Sex:Female Group:Training | Timepoint:4 weeks of training | Sex:Female Group:Training | Timepoint:4 weeks of training | Sex:Male Group:Training | Timepoint:4 weeks of training | Sex:Male Group:Training | Timepoint:4 weeks of training | Sex:Male Group:Training | Timepoint:4 weeks of training | Sex:Male Group:Training | Timepoint:4 weeks of training | Sex:Male Group:Training | Timepoint:8 weeks of training or control time | Sex:Female Group:Training | Timepoint:8 weeks of training or control time | Sex:Female Group:Training | Timepoint:8 weeks of training or control time | Sex:Female Group:Training | Timepoint:8 weeks of training or control time | Sex:Female Group:Training | Timepoint:8 weeks of training or control time | Sex:Female Group:Training | Timepoint:8 weeks of training or control time | Sex:Male Group:Training | Timepoint:8 weeks of training or control time | Sex:Male Group:Training | Timepoint:8 weeks of training or control time | Sex:Male Group:Training | Timepoint:8 weeks of training or control time | Sex:Male Group:Training | Timepoint:8 weeks of training or control time | Sex:Male Arachidonoyl-EA 0.0002 0.0003 0.0001 0.0001 0.0002 0.0001 0.0001 0.0003 0.0002 0.0001 0.0003 0.0000 0.0001 0.0025 0.0018 0.1635 0.3270 0.6541 1.3081 2.6163 5.2326 10.4651 20.9302 0.0001 0.0001 0.0001 0.0001 0.0000 0.0001 0.0005 0.0010 0.0009 0.0010 0.0006 0.0001 0.0005 0.0003 0.0003 0.0002 0.0001 0.0001 0.0001 0.0002 0.0001 0.0003 0.0002 0.0001 0.0002 0.0001 0.0002 0.0002 0.0001 0.0003 0.0001 0.0001 0.0002 0.0001 0.0001 0.0001 0.0001 0.0001 0.0002 0.0001 0.0001 0.0001 0.0001 0.0002 0.0002 0.0001 0.0000 0.0004 0.0001 0.0002 0.0001 0.0002 0.0003 0.0001 Docosahexenoyl-EA 0.0063 0.0065 0.0060 0.0060 0.0063 0.0061 0.0063 0.0075 0.0064 0.0060 0.0056 0.0068 0.0063 0.1726 0.3452 0.6904 1.3808 2.7616 5.5233 11.0465 22.0930 0.0062 0.0060 0.0062 0.0060 0.0061 0.0061 0.0063 0.0063 0.0062 0.0062 0.0060 0.0058 0.0060 0.0061 0.0060 0.0062 0.0058 0.0062 0.0060 0.0061 0.0061 0.0069 0.0064 0.0062 0.0066 0.0060 0.0061 0.0062 0.0061 0.0066 0.0064 0.0059 0.0063 0.0062 0.0061 0.0059 0.0058 0.0060 0.0061 0.0063 0.0061 0.0062 0.0065 0.0064 0.0066 0.0059 0.0057 0.0063 0.0060 0.0063 0.0061 0.0065 0.0065 0.0058 Oleoyl-EA 0.0006 0.0007 0.0006 0.0006 0.0007 0.0007 0.0006 0.0008 0.0007 0.0006 0.0005 0.0005 0.0005 0.0005 0.0007 0.0006 0.0164 0.0327 0.0654 0.1308 0.2616 0.5233 1.0465 2.0930 0.0009 0.0007 0.0009 0.0007 0.0010 0.0008 0.0006 0.0026 0.0025 0.0023 0.0005 0.0006 0.0005 0.0008 0.0010 0.0006 0.0005 0.0006 0.0006 0.0007 0.0006 0.0008 0.0006 0.0006 0.0007 0.0007 0.0006 0.0006 0.0006 0.0007 0.0007 0.0006 0.0007 0.0007 0.0006 0.0006 0.0006 0.0006 0.0006 0.0007 0.0006 0.0006 0.0006 0.0006 0.0007 0.0006 0.0006 0.0006 0.0006 0.0007 0.0006 0.0007 0.0007 0.0005 Palmitoyl-EA 0.1084 0.1373 0.0761 0.0871 0.1356 0.2164 0.0857 0.2795 0.1703 0.1053 0.0066 0.0109 0.0053 0.1726 0.3452 0.6904 1.3808 2.7616 5.5233 11.0465 22.0930 0.3694 0.2830 0.4146 0.3056 0.4246 0.3262 0.2586 0.2637 0.2382 0.2267 0.0522 0.0751 0.0524 0.1236 0.2206 0.1409 0.0589 0.1087 0.0799 0.1447 0.1114 0.3898 0.1387 0.1016 0.2178 0.1577 0.0818 0.0990 0.1065 0.1231 0.1908 0.0790 0.1615 0.1287 0.1023 0.0547 0.0487 0.1121 0.1116 0.1801 0.1530 0.1033 0.1422 0.1074 0.2082 0.0920 0.0644 0.0702 0.0837 0.1958 0.0770 0.1512 0.1482 0.0664 MS_METABOLITE_DATA_END #METABOLITES METABOLITES_START metabolite_name pubchem_id inchi_key kegg_id other_id other_id_type ri ri_type moverz_quant Arachidonoyl-EA 5.59 348.2 Docosahexenoyl-EA 6.47 372.3 Oleoyl-EA 6.7 326.4 Palmitoyl-EA 5.42 300.4 METABOLITES_END #END